Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5133-5143

  Krones Herzig, Anja ^a   Mittal, Shalu ^a   Yule, Kelly ^a   Liang, Hongyan ^b   English, Chris ^a   Urcis, Rafael ^a   Soni, Tarun ^a   Adamson, Eileen D ^b   Mercola, Dan ^a,b  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 6; PROTEIN P53; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GENETIC LINKAGE; GENETIC TRANSCRIPTION; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SENESCENCE; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME MAPPING; DNA DAMAGE; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; IMMEDIATE-EARLY PROTEINS; MALE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 20444474590     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3742     Document Type: Article

References (78)

1. Milbrandt J. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 1987;238:797-9.
2. Sukhatme VP, Cao XM, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988;53:37-43.
3. Huang RP, Wu JX, Fan Y, Adamson ED. UV activates growth factor receptors via reactive oxygen intermediates. J Cell Biol 1996;133:211-20.
4. Liu C, Rangnekar VM, Adamson E, Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1, Cancer Gene Ther 1998;5:3-28.
5. Liu C, Adamson E, Mercola D, Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor β1. Proc Natl Acad Sci U S A 1996;93:11831-6.
6. Gashler AL, Swaminathan S, Sukhatme VP. A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1. Mol Cell Biol 1993;13:4556-71.
7. Russo MW, Sevetson BR, Milbrandt J. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci U S A 1995;92:6873-7.
8. Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D. The transcription factor EGH-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-β1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem 1999;274:4400-11.
9. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment, of human gliobiastoma cell line U251. J Biol Chem 2000;275:20315-23.
10. Calogero A, Cuomo L, D'Onofrio M, et al. Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymprioid cell lines. Oncogene 1996;13:2105-12.
11. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102-9.
12. Calogero A, Arcella A, De Gregorio G, et al. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 2001;7:2788-96.
13. Levin WJ, Press MF, Gaynor RB, et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 1995;11:1261-9.
14. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997;272: 20131-8.
15. Das A, Chendil D, Dey S, et al. Ionizing radiation down-regulates p53 protein in primary Egr-1-/-mouse embryonic fibroblast cells causing enhanced resistance to apoptosis. J Biol Chem 2001;276:3279-86.
16. Liu J. Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ. Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 2001;18:863-70.
17. Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3: 1124-8.
18. Krones-Herzig A, Adamson E, Mercola D. Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci U S A 2003;100:3233-8.
19. Lee SL, Tourtellotte LC, Wesselschmidt RL, Mibrandt J. Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem 1995;270:9971-7.
20. Topilko P, Levi G, Merlo G, et al. Differential regulation of the zinc finger genes Krox-20 and Krox-24 (Egr-1) suggests antagonistic roles in Schwann cells. J Neurosci Res 1997;50:702-12.
21. Robertson EJ. Teratocarcinomas and embryonic stem cells: a practical approach. In: Rickward DaH, editor. Practical approach series. Oxford: IRL Press; 1987. p. 71-112.
22. Bulletin AC. GeneChip® expression analysis data analysis fundamentals; 2005. Available from: http://www.affymetrix.com.
23. Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997;15:1359-67.
24. de Belle I, Mercola D, Adamson ED. Method for cloning in vivo targets of the Egr-1 transcription factor. Biotechniques 2000;29:162-9.
25. Perchellet JP, Boutwell RK. Comparison of the effects of 3-isobutyl-1-methylxanthine and adenosine cyclic 3′:5′-monophosphate on the induction of skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process. Carcinogenesis 1982; 3:53-60.
26. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000;275:38524-31.
27. Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalona WJ, Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol 2001;32:935-9.
28. Dinkel A, Aicher WK, Haas C, Zipfel PF, Peter HH, Eibel H. Transcription factor Egr-1 activity down-regulates Fas and CD23 expression in B cells. J Immunol 1997;59:2678-84.
29. Adamson E, de Belle I, Mittal S, et al. Egr1 signaling in prostate cancer. Cancer Biol Ther 2003;2:617-22.
30. Liu C, Calogero A, Ragona G, Adamson E, Mercola D, EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-β1 is postulated to account for this suppressor activity. Crit Rev Oncog 1996;7:101-25.
31. Liu J, Clegg CH, Shoyab M. Regulation of EGR-1, c-jun, and c-myc gene expression by oncostatin M. Cell Growth Differ 1992;3:307-13.
32. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84.
33. de Belle I, Huang RP, Fan Y, Liu C, Mercola D, Adamson ED. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 1999;18:3633-42.
34. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 2003;278:11S02-10.
35. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74:813-22.
36. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor α. Cancer Res 1996;56:4413-23.
37. Weinberg WC, Fernandez-Salas E, Morgan DL, et al. Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res 1999; 59:2050-4.
38. Ahmed MM, Venkatasubbarao K, Fruitwala SM, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 1996;271: 29231-7.
39. Baron V, De Gregorio G, Krones-Herzig A. et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 2003;22:4194-204.
40. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW. Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 1996;55:975-81.
41. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of early growth response genes in human prostate cancer. Cancer Res 1998;58:2461-8.
42. Scharnhorst V, Menke AL, Attema J, et al. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 2000;19:791-800.
43. Fahmy RG, Khachigian LM. Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. J Cell Biochem 2002;84:575-82.
44. Khachigian LM. DNAzymes: cutting a path to a new class of therapeutics. Curr Opin Mol Ther 2002;4: 119-21.
45. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
46. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
47. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71:587-97.
48. Zhan Q, Fan S, Smith ML, et al. Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. DNA Cell Biol 1996;15: 805-15.
49. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
50. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188: 2033-45.
51. Munsch D, Watanabe-Fukunaga R, Bourdon JC, et al. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 2000;275:3867-72.
52. Massague J, Weinberg RA, Negative regulators of growth. Curr Opin Genet Dev 1992;2:28-32.
53. Skonier J, Bennett K, Rothwell V, et al. βig-h3: a transforming growth factor-β-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 1994;13:571-84.
54. Shainkin-Kestenbaum R, Zimlichman S, Lis M, et al. Effect of serum amyloid A, HDL-apolipoprotein, on endothelial cell proliferation. Implication of an enigmatic protein to atherosclerosis. Biomed Pept Proteins Nucleic Acids 1996;2:79-84.
55. Home MC, Donaldson KL, Goolsby GL, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem 1997;272:12650-61.
56. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 2002;13: 1893-905.
57. Sabatelli P, Bonaldo P, Lattanzi G. et al. Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol 2001;20:475-86.
58. Guthridge MA, Seldin M, Basilico C. Induction of expression of growth-related genes by FGF-4 in mouse fibroblasts. Oncogene 1996;12:1267-78.
59. Gudas JM, Payton M, Thukral S, et al. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 1999;19: 612-22.
60. 1-S transition in primary hepatocytes. Biochem Biophys Res Commun 1999;261:118-22.
61. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ III, Kim SJ. Repression of the transforming growth factor-β1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 1994;8: 595-602.
62. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995;92: 5545-9.
63. 1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 1993; 260:536-9.
64. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
65. Collado M, Medema RH, Garcia-Cao I, et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000;275:21960-8.
66. 1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A 1998;95: 15406-11.
67. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:571-83.
68. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 1997;94:7245-50.
69. ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
70. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A 2002;99: 12985-90.
71. Stephan H, Grosse F, Soe K. Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro. Nucleic Acids Res 2002;30:5087-93.
72. Wang QE, Zhu Q, Wani MA, Wani G, Chen J, Wani AA. Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair (Amst) 2003;2:483-99.
73. Topilko P, Schneider-Maunoury S, Levi G, et al. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol Endocrinol 1998; 12:107-22.
74. Tourtellotte WG, Nagarajan R, Bartke A, Milbrandt J. Functional compensation by Egr4 in Egr1-dependent luteinizing hormone regulation and Leydig cell steroidogenesis. Mol Cell Biol 2000;20:5261-8.
75. Gyotoku E, Morita E, Kameyoshi Y, Hiragun T, Yamamoto S, Hide M. The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice. Arch Dermatol Res 2001;293:508-14.
76. Chung L, Issacs W, Simons J. Prostate cancer. 1st ed. Totowa (NJ): Humana Press, Inc.: 2001. p. 531.
77. Khachigian LM, Collins T. Early growth response factor 1: a pleiotropic mediator of inducible gene expression. J Mol Med 1998;76:613-6.
78. Van SF, Lu J, Zou YS, et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999;274:15030-40.